BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld Asia
Home
» With a majority stake in Ruide, Australia's CSL becomes the Chinese market leader
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
With a majority stake in Ruide, Australia's CSL becomes the Chinese market leader
June 21, 2017
By
David Ho
No Comments
HONG KONG – CSL Ltd. has bought a majority stake in China's Wuhan Zhong Yuan Ruide Biological Products Co. Ltd. in a $352 million deal that should make the Australian biotech company a market leader.
BioWorld Asia